Note: Ingredients listed on restricted chemical lists
EC/CAS
16731-55-8
Name of the chemical
Dipotassium disulphite
Concentration
N/A
EC/CAS
123-31-9
Name of the chemical
1,4-Dihydroxybenzol (790/2009)
Concentration
N/A
EC/CAS
1310-58-3
Name of the chemical
potassium hydroxide
Concentration
N/A
General Information
Revision date
2004-04-13
Product name
Cinerex PD Developer/Replenisher
Product Synonyms
Vericath PD Developer
Chemical name
Cinerex PD Developer/Replenisher
Icons in SDS
Company Information
company name
AGFA CORPORATION
GHS Information
Signal word
WARNING!
Section 2
SECTION 2: Hazards identification
This product as a whole has not been tested. This hazard information is for the individual ingredients. ***************************************************************** * EMERGENCY OVERVIEW * WARNING! Color Clear to pale straw; Form Liquid; Odor * * Odorless; May cause respiratory tract irritation; May cause * * allergic respiratory reaction; Causes skin irritation; May * * cause allergic skin reaction; Causes eye irritation; May be * * harmful if swallowed; Irritating gases/fumes may be given * * off during burning or thermal decomposition. * *****************************************************************
Potential health effects
ROUTES OF ENTRY..................: Eye and skin contact, inhalation of vapors or mists, accidental ingestion. HUMAN EFFECTS AND SYMPTOMS OF OVEREXPOSURE: ACUTE INHALATION..............: The potassium metabisulfite, hydroquinone and sodium metaborate tetrahydrate in this product are expected to be irritating to the respiratory tract with symptoms of coughing, sore throat, and runny nose. Potassium metabisulfite may cause an allergic reaction in some asthmatics and sulfite sensitive individuals. Possible symptoms include bronchoconstriction, sweating, flushing, hives, rapid heart rate, decreased blood pressure, and anaphylaxis. Inhalation of potassium hydroxide vapors can cause respiratory tract irritation with symptoms of coughing, choking, runny nose, and possible burns of the mucous membranes. CHRONIC INHALATION............: Persons who have been previously sensitized to sulfites should take precautions to prevent the inhalation of potassium metabisulfite. Prolonged exposure to high concentrations of potassium hydroxide may cause discomfort and ulceration of the nasal passages. Prolonged inhalation of potassium bromide may cause skin eruptions. ACUTE SKIN CONTACT............: Potassium metabisulfite, sodium metaborate tetrahydrate and hydroquinone can be irritating to the skin with symptoms of reddening, itching, and swelling. Hydroquinone may cause skin sensitization with symptoms of rash, itching, hives, and swelling. Contact with potassium hydroxide can be corrosive to the skin with symptoms of itching, reddening, swelling, and burning. CHRONIC SKIN CONTACT..........: Sensitization with dermatitis or hives may occur. ACUTE EYE CONTACT.............: Potassium metabisulfite, potassium metaborate tetrahydrate, 1-Phenyl-3-pyrazolidone and hydroquinone can be irritating to the eyes with symptoms of tearing, stinging, reddening, and swelling. Contact with potassium hydroxide can be corrosive to the eyes resulting in burning, itching, reddening, swelling of the eye and surrounding tissue and clouding of the cornea. CHRONIC EYE CONTACT...........: Repeated exposure to hydroquinone may cause intolerance of the eyes to light. In addition, repeated overexposure to hydroquinone may cause pigment deposition, which can extend into the cornea with continued exposure to high concentrations. This pigment deposition does not impair vision. ACUTE INGESTION...............: Ingestion of this product may cause gastrointestinal irritation. Hydroquinone may be harmful if swallowed with symptoms including nausea, vomiting, drowsiness, dizziness, disorientation, bluish skin color, and stomach pain. Ingestion of potassium hydroxide solutions may cause burning pain in the mouth, throat, esophagus and abdomen. 1-Phenyl-3-pyrazolidone is expected to be harmful if swallowed. OTHER EFFECTS OF EXPOSURE.....: See Section 11. CARCINOGENICITY...............: The components of this product are not listed by NTP, IARC or regulated as a carcinogen by OSHA. MEDICAL CONDITIONS AGGRAVATED BY EXPOSURE......: Persons with preexisting eye or skin conditions or impaired pulmonary function may be more susceptible to the effects of this product.